InsiderTrades.com logo
Patrick John Finn net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Patrick Finn Biography and Net Worth

Insider of Verona Pharma PLC American Depositary Share
Patrick John Finn Ph.D. serves as Chief Commercial Officer of the Company. He is our Senior Vice President of Commercial Operations from December 2018 to October 2019. Prior to joining us, Dr. Finn was Vice President of Sales at Enzymatics Inc., a developer, manufacturer, and marketer of enzymes for molecular biology applications, sold predominantly to manufacturers in research and diagnostic markets from January 2012 to March 2015. Dr. Finn holds a B.Sc. in Chemistry from Heriot-Watt University and a Ph.D. in Chemistry from the University of Southampton.

What is Patrick John Finn's net worth?

The estimated net worth of Patrick John Finn is at least $25.74 million as of May 21st, 2025. Mr. Finn owns 240,783 shares of Verona Pharma PLC American Depositary Share stock worth more than $25,742,111 as of December 4th. This net worth approximation does not reflect any other investments that Mr. Finn may own. Learn More about Patrick John Finn's net worth.

How do I contact Patrick John Finn?

The corporate mailing address for Mr. Finn and other Verona Pharma PLC American Depositary Share executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma PLC American Depositary Share can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Patrick John Finn's contact information.

Has Patrick John Finn been buying or selling shares of Verona Pharma PLC American Depositary Share?

Patrick John Finn has not been actively trading shares of Verona Pharma PLC American Depositary Share in the last ninety days. Learn More on Patrick John Finn's trading history.

Who are Verona Pharma PLC American Depositary Share's active insiders?

Verona Pharma PLC American Depositary Share's insider roster includes Christina Ackermann (Director), Michael Austwick (Director), James Brady (Director), Kenneth Cunningham (Director), Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Andrew Fisher (General Counsel), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Mahendra Shah (Director), Vikas Sinha (Director), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma PLC American Depositary Share's active insiders.

Are insiders buying or selling shares of Verona Pharma PLC American Depositary Share?

In the last year, insiders at the sold shares 32 times. They sold a total of 3,057,968 shares worth more than $30,187,074.16. The most recent insider tranaction occured on August, 1st when Director Kenneth Cunningham sold 10,808 shares worth more than $142,017.12. Insiders at Verona Pharma PLC American Depositary Share own 4.8% of the company. Learn More about insider trades at Verona Pharma PLC American Depositary Share.

Information on this page was last updated on 8/1/2025.

Patrick John Finn Insider Trading History at Verona Pharma PLC American Depositary Share

See Full Table

Patrick John Finn Buying and Selling Activity at Verona Pharma PLC American Depositary Share

This chart shows Patrick John Finn's buying and selling at Verona Pharma PLC American Depositary Share by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma PLC American Depositary Share Company Overview

Verona Pharma PLC American Depositary Share logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $106.91
Low: $106.91
High: $106.91

50 Day Range

MA: $106.65
Low: $105.91
High: $106.95

2 Week Range

Now: $106.91
Low: $31.09
High: $106.93

Volume

N/A

Average Volume

1,457,608 shs

Market Capitalization

$9.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05